Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Hunzelmann

Showing results (111-120 of 135) with videos related to

Pageof 14
Sort By:
The British Journal of Dermatology|February 3, 2009
Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factorsC Sunderkötter, I Herrgott, C Brückner, et al.
Rheumatology (Oxford, England)|December 6, 2008
Skin sclerosis is only of limited value to identify SSc patients with severe manifestations--an analysis of a distinct patient subgroup of the German Systemic Sclerosis Network (DNSS) RegisterL G Hanitsch, G-R Burmester, C Witt, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 17, 2020
Whole blood gene expression profiling distinguishes systemic sclerosis-overlap syndromes from other subsetsP Moinzadeh, P Frommolt, M Franitza, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 30, 2012
Randomized, double-blind, placebo-controlled study of safety and efficacy of miltefosine in antihistamine-resistant chronic spontaneous urticariaM Magerl, M Rother, T Bieber, et al.
Annals of the Rheumatic Diseases|June 1, 2010
Association of the TNFAIP3 rs5029939 variant with systemic sclerosis in the European Caucasian populationP Dieudé, M Guedj, J Wipff, et al.
Arthritis and Rheumatism|October 31, 2009
BANK1 is a genetic risk factor for diffuse cutaneous systemic sclerosis and has additive effects with IRF5 and STAT4P Dieudé, J Wipff, M Guedj, et al.
Genes and Immunity|May 4, 2012
Evidence that deletion at FCGR3B is a risk factor for systemic sclerosisC McKinney, J C A Broen, M C Vonk, et al.
Arthritis Care & Research|June 1, 2019
Large Variability of Frequency and Type of Physical Therapy in Patients in the German Network for Systemic SclerosisD Belz, P Moinzadeh, G Riemekasten, et al.
Rheumatology (Oxford, England)|July 22, 2024
Preventive effects of early immunosuppressive treatment on the development of interstitial lung disease in systemic sclerosisA Velauthapillai, M F R Bootsma, C Bruni, et al.
The British Journal of Dermatology|December 29, 2015
The Predict Study: low risk for digital ulcer development in patients with systemic sclerosis with increasing disease duration and lack of topoisomerase-1 antibodiesN Hunzelmann, G Riemekasten, M O Becker, et al.
Pageof 14

Showing results (111-120 of 135) with videos related to

Sort By:
Pageof 14
The British Journal of Dermatology|February 3, 2009
Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factorsC Sunderkötter, I Herrgott, C Brückner, et al.
Rheumatology (Oxford, England)|December 6, 2008
Skin sclerosis is only of limited value to identify SSc patients with severe manifestations--an analysis of a distinct patient subgroup of the German Systemic Sclerosis Network (DNSS) RegisterL G Hanitsch, G-R Burmester, C Witt, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 17, 2020
Whole blood gene expression profiling distinguishes systemic sclerosis-overlap syndromes from other subsetsP Moinzadeh, P Frommolt, M Franitza, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 30, 2012
Randomized, double-blind, placebo-controlled study of safety and efficacy of miltefosine in antihistamine-resistant chronic spontaneous urticariaM Magerl, M Rother, T Bieber, et al.
Annals of the Rheumatic Diseases|June 1, 2010
Association of the TNFAIP3 rs5029939 variant with systemic sclerosis in the European Caucasian populationP Dieudé, M Guedj, J Wipff, et al.
Arthritis and Rheumatism|October 31, 2009
BANK1 is a genetic risk factor for diffuse cutaneous systemic sclerosis and has additive effects with IRF5 and STAT4P Dieudé, J Wipff, M Guedj, et al.
Genes and Immunity|May 4, 2012
Evidence that deletion at FCGR3B is a risk factor for systemic sclerosisC McKinney, J C A Broen, M C Vonk, et al.
Arthritis Care & Research|June 1, 2019
Large Variability of Frequency and Type of Physical Therapy in Patients in the German Network for Systemic SclerosisD Belz, P Moinzadeh, G Riemekasten, et al.
Rheumatology (Oxford, England)|July 22, 2024
Preventive effects of early immunosuppressive treatment on the development of interstitial lung disease in systemic sclerosisA Velauthapillai, M F R Bootsma, C Bruni, et al.
The British Journal of Dermatology|December 29, 2015
The Predict Study: low risk for digital ulcer development in patients with systemic sclerosis with increasing disease duration and lack of topoisomerase-1 antibodiesN Hunzelmann, G Riemekasten, M O Becker, et al.
Pageof 14